Olivetolic Acid Biosynthesis Platform for High-Titer Cannabinoid Analogues
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low abundance of cannabinoids in native plants and legal scheduling of Cannabis have hindered in-depth studies on their therapeutic benefits, and existing fermentation-based processes face challenges such as low availability of starting units and limited production of cannabinoid analogues.
Innovation Solution
A biosynthetic platform comprising enzymes like non-reducing polyketide synthase (NRPKS) and thioesterase, derived from organisms like Metarhizium anisopliae, converts simpler metabolites into olivetolic acid and its analogues, with a cell-free system enabling high-titer production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional fermentation-based processes are used to produce cannabinoids, then production can be achieved, but the availability of starting units is limited and production of cannabinoid analogues is restricted
Solution Approach 1:
The patent divides the cannabinoid biosynthesis pathway into modular enzymatic components (NRPKS, HRPKS, thioesterase) that can be independently optimized and recombined. This segmentation allows separate optimization of starter unit production and core biosynthesis, resolving the contradiction between limited starting units and analogue diversity.
Solution Approach 2:
The engineered NRPKS enzyme is designed with broad substrate acceptance to process multiple different starter units (hexanoyl-CoA, octanoyl-CoA, and their analogues) through a single catalytic domain. This multi-functionality enables production of diverse cannabinoid analogues from varied starting materials, simultaneously addressing both productivity and versatility requirements.
2Quantity of substance
If native plant sources are used for cannabinoid production, then natural cannabinoids can be obtained, but abundance is low and legal scheduling limits research and application
Solution Approach 1:
The patent uses engineered microbial systems as intermediary factories that convert readily available metabolites into cannabinoids through introduced biosynthetic pathways. This intermediary approach bypasses the need for native plant cultivation while maintaining natural cannabinoid production, resolving both abundance and accessibility issues.
Solution Approach 2:
The biosynthetic pathway is designed to utilize endogenous microbial metabolites (acetyl-CoA, malonyl-CoA, hexanoyl-CoA) as substrates, allowing the system to be self-sufficient. The microbes serve their own metabolic needs while simultaneously producing cannabinoids, eliminating dependency on external starting materials and enhancing both abundance and ease of manufacture.
3Productivity
If existing biosynthetic pathways are used, then cannabinoid production is achieved, but production titers remain low and analogue diversity is limited
Solution Approach 1:
The patent systematically varies key parameters including starter unit chain length (C6, C8), degree of reduction (saturated vs. unsaturated), and enzyme expression levels to optimize both production titer and analogue diversity. By changing these parameters, the system achieves high-yield production while generating diverse cannabinoid structures.
Solution Approach 2:
The patent creates composite biosynthetic systems combining multiple enzyme types (NRPKS, HRPKS, thioesterase) from different organisms into a functional pathway. This composite approach integrates the advantages of each enzyme type, achieving both high productivity through efficient catalysis and high versatility through broad substrate acceptance across the enzyme complex.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform achieves high-yield production of olivetolic acid and analogues, overcoming limitations of traditional methods by generating diverse cannabinoid structures efficiently.
Implementation Method 1
a non-reducing polyketide synthase (NRPKS) that converts a set of metabolites comprising hexanoyl-CoA, hexanoic acid, octanoyl-CoA, octanoic acid, and/or analogs thereof to an aromatic diol metabolite
Implementation Method 2
a thioesterase that converts the aromatic diol metabolite to olivetolic acid and analogues thereof
Implementation Method 3
a highly-reducing polyketide synthase (HRPKS) that utilizes acetyl-CoA, malonyl-CoA, and NADPH to synthesize the set of metabolites selected from hexanoyl-CoA, hexanoic acid, octanoyl-CoA, octanoic acid, and/or analogs thereof
Data Source
AI summary
The disclosure provides biosynthetic platforms that generate olivetolic acid and its analogues at high titers from microbes, and in cell free systems.